他汀类药物在心力衰竭中的研究：炎症生物标志物与激素

Investigations of statins in heart failure: inflammatory biomarkers and hormones.

作者信息

Khan Bobby V, Rajagopalan Sanjay

机构信息

Emory University School of Medicine, Atlanta, GA, USA.

出版信息

Heart Fail Clin. 2008 Apr;4(2):171-6. doi: 10.1016/j.hfc.2008.01.003.

DOI:10.1016/j.hfc.2008.01.003

PMID:18433697

Abstract

The primary role of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) is to treat dyslipidemia. The clinical benefits with statin therapy have been demonstrated in the primary and secondary prevention of atherosclerotic vascular diseases. More recently, it has been observed that pleiotropic effects of statins (which may or may not be associated with lipid lowering) have been described as treatment of various cardiovascular disease processes and in noncardiac disease processes. This article evaluates the potential mechanisms for these effects in the management of heart failure and postulates their clinical and beneficial use.

摘要

3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂（他汀类药物）的主要作用是治疗血脂异常。他汀类药物治疗的临床益处已在动脉粥样硬化性血管疾病的一级和二级预防中得到证实。最近，人们观察到他汀类药物的多效性作用（可能与降脂有关，也可能无关）已被描述用于治疗各种心血管疾病过程以及非心脏疾病过程。本文评估了这些作用在心力衰竭管理中的潜在机制，并推测了它们的临床应用及益处。